1971-P: Clinical Characteristics and Economic Burden of Diabetic Ketoacidosis in People with Type 1 Diabetes in the U.S.

Introduction and Objective: Diabetic ketoacidosis (DKA) is the most common acute complication of diabetes. In this study, we assessed the clinical characteristics and costs of DKA hospitalizations in people with type 1 diabetes (T1D). Methods: We searched the 2022 National Inpatient Sample database for people with T1D (E10.xx any position) and DKA hospitalizations using ICD-10 codes (E10.1, E10.10, E10.11, principal diagnosis at discharge). We reported incidence, length of stay (LOS) using mean and standard deviation (SD), mortality using frequency (%), and hospitalization costs. Results: Among 382,460 hospitalizations in patients with T1D, 34.1% (n: 130,465) had DKA as the principal diagnosis, corresponding to 341.1 per 1,000 T1D hospitalizations (Table). The average LOS was 3.1 (4.7) days. The inpatient mortality was 0.3% (n: 385). The mean cost per hospitalization was $10,140 (12,350). Conclusion: This analysis provides recent national estimates of the incidence, LOS, mortality and cost of hospitalizations for DKA in people with T1D. One-third of hospitalizations in people with T1D in the U.S. were for DKA in 2022, with a total cost exceeding $1.24 billion, highlighting a significant burden to patients and the health system. Disclosure R.J. Galindo: Consultant; Ended; Abbott, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Novo Nordisk, Medtronic. Research Support; Current; Roche Pharmaceuticals, Boehringer Ingelheim International GmbH, Novo Nordisk. N. Virdi: Employee; Current; Abbott Diabetes. A. Lee: Employee; Current; Abbott Diabetes. Y. Poon: Employee; Current; Abbott Diabetes. Stock/Shareholder; Current; Abbott Diabetes. Funding Abbott Diabetes Care